Lupin - Public Comps and Valuation Multiples

Lupin Overview

About Lupin

Lupin Ltd is a specialty and generic drug manufacturing company. The company produces, develops, and markets branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs) globally. It has a presence in the Cardiovascular, Diabetology, Asthma, Pediatrics, Central Nervous System, GastroIntestinal, and other drug therapy segments. The operations of the company are limited to the segments, namely pharmaceuticals which derives key revenue, and others. It also maintains a pipeline in high-barrier markets such as Inhalation, Biosimilars, and Complex Injectables. The vast majority of the company's sales are generated in the United States, followed by India, and other countries.

Founded

1983

HQ

Employees

26.2K+

Website

lupin.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $2.7B

LTM EBITDA $664M

EV

$10.3B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Lupin Financials

As of September 2025, Lupin reported last 12-month revenue of $2.7B and EBITDA of $664M.

In the same period, Lupin generated $1.9B in LTM gross profit and $425M in net income.

See Lupin valuation multiples based on analyst estimates

Lupin P&L

In the most recent fiscal year, Lupin reported revenue of $2.5B and EBITDA of $615M.

Lupin expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Lupin valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$2.7B	XXX	$2.5B	XXX	XXX	XXX
Gross Profit	$1.9B	XXX	$1.7B	XXX	XXX	XXX
Gross Margin	70%	XXX	66%	XXX	XXX	XXX
EBITDA	$664M	XXX	$615M	XXX	XXX	XXX
EBITDA Margin	24%	XXX	25%	XXX	XXX	XXX
EBIT	$537M	XXX	$490M	XXX	XXX	XXX
EBIT Margin	20%	XXX	20%	XXX	XXX	XXX
Net Profit	$425M	XXX	$370M	XXX	XXX	XXX
Net Margin	16%	XXX	15%	XXX	XXX	XXX
Net Debt	XXX	XXX	$355M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for Lupin including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $2.7B. EBITDA for the last twelve months was $664M. In the most recent fiscal year, Lupin achieved $2.5B in revenue and $615M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$2.7B	Analyst estimates available to subscribers	$2.5B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$1.9B	Analyst estimates available to subscribers	$1.7B	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	70.4% gross margin	Analyst estimates available to subscribers	66.4% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$664M	Analyst estimates available to subscribers	$615M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	24.4% EBITDA margin	Analyst estimates available to subscribers	24.6% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$537M	Analyst estimates available to subscribers	$490M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	19.7% EBIT margin	Analyst estimates available to subscribers	19.6% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$425M	Analyst estimates available to subscribers	$370M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	15.6% net profit margin	Analyst estimates available to subscribers	14.8% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$355M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for Lupin

This financial data table provides comprehensive performance metrics for Lupin, a company based in India. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

Lupin generated $2.7B in revenue over the last twelve months.
The company achieved $664M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $1.9B.
Net income over the last twelve months reached $425M.

Fiscal Year Performance

In the most recent fiscal year, Lupin reported $2.5B in total revenue.
Fiscal year EBITDA was $615M.
The company maintained a gross profit margin of 66.4% in the most recent fiscal year.
EBITDA margin for the fiscal year was 24.6%.
Net profit margin reached 14.8% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for Lupin. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

Lupin Stock Performance

Lupin has current market cap of INR 891B (or $10.0B), and EV of INR 915B (or $10.3B).

Market Cap Evolution

Lupin Stock Data

As of October 17, 2025, Lupin's stock price is INR 1951 (or $22).

See Lupin trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$10.3B	$10.0B	XXX	XXX	XXX	XXX	$0.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

Lupin Valuation Multiples

Lupin's trades at 4.2x EV/Revenue multiple, and 18.1x EV/EBITDA.

See valuation multiples for Lupin and 15K+ public comps

Lupin Financial Valuation Multiples

As of October 17, 2025, Lupin has market cap of $10.0B and EV of $10.3B.

Equity research analysts estimate Lupin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Lupin has a P/E ratio of 23.6x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$10.0B	XXX	$10.0B	XXX	XXX	XXX
EV (current)	$10.3B	XXX	$10.3B	XXX	XXX	XXX
EV/Revenue	3.8x	XXX	4.2x	XXX	XXX	XXX
EV/EBITDA	15.5x	XXX	18.1x	XXX	XXX	XXX
EV/EBIT	19.2x	XXX	23.1x	XXX	XXX	XXX
EV/Gross Profit	5.4x	XXX	n/a	XXX	XXX	XXX
P/E	23.6x	XXX	30.3x	XXX	XXX	XXX
EV/FCF	40.0x	XXX	54.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Lupin Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

Lupin Margins & Growth Rates

Lupin's last 12 month revenue growth is 8%

Lupin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $45K for the same period.

Lupin's rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Lupin's rule of X is 44% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for Lupin and other 15K+ public comps

Lupin Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	8%	XXX	10%	XXX	XXX	XXX
EBITDA Margin	24%	XXX	23%	XXX	XXX	XXX
EBITDA Growth	7%	XXX	12%	XXX	XXX	XXX
Rule of 40	31%	XXX	31%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	44%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.1M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$45K	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	6%	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	47%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial